This week in MathOnco 153

Cell-cell/resource interactions; dose personalization; public goods; branching process

“This week in Mathematical Oncology” — Newsletter

Mar. 11, 2021
>jeffrey.west@moffitt.org

From the editor:


Summary of contents:

• Measuring frequency/density/resource dependent interactions

• A stochastic branching process model examining the site frequency spectrum metric

• A blog post on adaptive dose personalization

• Public goods game extension of replicator dynamics

• An editorial on tumor cell plasticity

• … and more

Enjoy,
-Jeffrey West

1. Frequency-dependent interactions determine outcome of competition between two breast cancer cell lines
   Audrey R. Freischel, Mehdi Damaghi, Jessica J. Cunningham, Arig Ibrahim-Hashim, Robert J. Gillies, Robert A. Gatenby, Joel S. Brown

2. Paracrine behaviors arbitrate parasite-like interactions between tumor subclones
   Robert J. Noble, Viola Walther, Christian Roumestand, Urszula Hibner, Michael E. Hochberg, Patrice Lassus

3. Mechanistic models for hematological toxicities: Small is beautiful
   Laure Deyme, Sébastien Benzekry, Joseph Ciccolini

4. Editorial: Characterizing the Multi-Faceted Dynamics of Tumor Cell Plasticity
   Satyendra Chandra Tripathi, Mohit Kumar Jolly, Sendurai A. Mani, Herbert Levine

5. OncoTree: A Cancer Classification System for Precision Oncology
   Ritika Kundra, Hongxin Zhang, Robert Sheridan, Sahussapont Joseph Sirintrapun, …, Angela Waanders, Jianjiong Gao, David Solit, Nikolaus Schultz

6. Role of neutrophil extracellular traps in regulation of lung cancer invasion and metastasis: Structural insights from a computational model
   Junho Lee, Donggu Lee, Sean Lawler, Yangjin Kim

7. An evolutionary dynamics model for metastatic tumour growth based on public goods games
   Jose M. Sanz Nogales, S. Zazo

1. Exact site frequency spectra of neutrally evolving tumors, transition between power laws and signatures of cell viability
   Einar Bjarki Gunnarsson, Kevin Leder, Jasmine Foo

2. Clinical Data Validated Mathematical Model for Intermittent Abiraterone Response in Castration-Resistant Prostate Cancer Patients (SIAM Undergraduate Research Online)
   Justin Bennett, Karissa Gund, Jingteng iLu, Xixu Hu, Anya Porter

3. Cell and Nucleus Shape as an Indicator of Tissue Fluidity in Carcinoma
   Steffen Grosser, Jürgen Lippoldt, Linda Oswald, Matthias Merkel, …, Susanne Briest, Bahriye Aktas, M. Lisa Manning, Josef A. Käs
   

1. Adaptive dose personalization: what's first, what's second?
The Mathematical Oncology Blog

Jeffrey West & Maximilian Strobl: “Adaptive cancer treatment in prostate cancer has two distinct differences from standard of care protocols. First, it consists of a personalized dosing protocol dictating treatment holidays based on a patient-specific biomarker. Second, these treatment holidays result in a much lower cumulative dose delivered over the course of the patient's treatment regimen (53% less). Which is more important? Is it even possible to determine if scheduling is more important than total dose delivered?”

Atomic Habits:
An Easy & Proven Way to Build Good Habits & Break Bad Ones

James Clear: "If you're having trouble changing your habits, the problem isn't you. The problem is your system. Bad habits repeat themselves again and again not because you don't want to change, but because you have the wrong system for change. You do not rise to the level of your goals. You fall to the level of your systems. Here, you'll get a proven system that can take you to new heights."

• Networks in Cancer: From Symmetry Breaking to Targeted Therapy
  Guest Editor: Cristian Axenie, Roman Bauer, María Rodríguez Martínez

• Understanding the Evolutionary Dynamics and Ecology of Cancer in Treatment Resistance
  Guest Editor: David Basanta

• Mathematical Models of Cellular Immunotherapies in Cancer
  Guest Editors: V. Pérez-García, L. de Pillis, P. Altrock, R. Rockne

• From Ecology to Cancer Biology and Back Again
  Guest Editors: Fred Adler, Sarah Amend, Chris Whelan

• Frontiers in quantitative cancer modeling
  Guest Editors: Mohit Kumar Jolly, Heiko Enderling

• PhD Position - Simulation of Tissue (Jakob Rosenbauer)

• Postdoc on colorectal cancer evolution or cancer immunotherapy (Ivana Bozic)

• PhD student in modeling evolution and ecology of cancer (Rob Noble)

• Postdoc on cancer/immune modeling and machine learning (Eduardo Sontag)

• PhD candidate/Early Career Researcher: Theory of Stackelberg evolutionary games for cancer treatment (Katerina Stankova)

• Early Stage Researcher: Impact of different resistance mechanisms on the outcomes of cancer treatment game (Weini Huang)

• Early Stage Researcher: Evolutionary therapy in ovarian cancer (Ben Werner)

• CDC Steven M. Teutsch Prevention Effectiveness Fellowship

• Mathematical Modeling Expert in Oncology Translational Science (Boehringer Ingelheim)

• Research Associate - Biostatistician (University of Manchester)

• Postdoctoral Fellow in Cancer Resistance Modeling, Pfizer (Blerta Shtylla)

• Director Quantitative Clinical Pharmacology, Oncology

• Principal Scientist – Oncology PK/PD Modelling (Boehringer Ingelheim)

• Biosimulation Scientist (Physiomics)

• Postdoctoral Research Position in Computational Immunology (Sylvain Cussat-Blanc)

• Systems Biology Modeler Positions in Biopharma Consulting Company (Helen Moore)

• Computational Approaches to Breast Cancer Evolution - Postdoc (Marc Ryser)

• Math/statistical models of stem cell lineage dynamics and cancer genomics - Postdoc (Adam MacLean)

• Machine Learning / Math Modeling Postdoc (Noemi Andor)

• Cancer immunotherapy / systems bio postdoc (Elana J Fertig)

• Integrated Math Oncology Ph.D. (Moffitt)

• Integrated Math Oncology Postdoc (Sandy Anderson)

• Postdoctoral Research Position in Computational Oncology (Tom Yankeelov)

---

Current subscriber count: 901